Australasian chronic lymphocytic leukaemia consensus statement: 2026 update

IF 1.8 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Internal Medicine Journal Pub Date : 2026-08-10 Epub Date: 2026-07-07 DOI:10.1111/imj.70503

Sean McKeague, Joanna Katarzyna Czerwinski, Xavier Badoux, Rory Bennett, Giles Best, Nicole Chia, Tara Cochrane, Kyle Crassini, Gavin Cull, Pietro Di Ciaccio, Pasquale Fedele, Rosemary Harrup, Sharon Jackson, Bryone Kuss, Masa Lasica, Denise Lee, Thomas Lew, Paula Marlton, Monique Menzies Wojtowicz, Stephen Opat, Sumita Ratnasingam, John Francis Seymour, Dipti Talaulikar, Constantine Si Lun Tam, Robert Weinkove, Joel Wight, Stephen Mulligan, Mary Ann Anderson

{"title":"Australasian chronic lymphocytic leukaemia consensus statement: 2026 update","authors":"Sean McKeague, Joanna Katarzyna Czerwinski, Xavier Badoux, Rory Bennett, Giles Best, Nicole Chia, Tara Cochrane, Kyle Crassini, Gavin Cull, Pietro Di Ciaccio, Pasquale Fedele, Rosemary Harrup, Sharon Jackson, Bryone Kuss, Masa Lasica, Denise Lee, Thomas Lew, Paula Marlton, Monique Menzies Wojtowicz, Stephen Opat, Sumita Ratnasingam, John Francis Seymour, Dipti Talaulikar, Constantine Si Lun Tam, Robert Weinkove, Joel Wight, Stephen Mulligan, Mary Ann Anderson","doi":"10.1111/imj.70503","DOIUrl":null,"url":null,"abstract":"<p>In 2023, a consensus statement on the diagnosis and management of chronic lymphocytic leukaemia (CLL) in Australasia was published. Since then, advances in clinical evidence and increased availability of molecular diagnostics and targeted therapies have further influenced contemporary CLL management. This paper provides an expert consensus update to the 2023 statement, offering current, regionally relevant guidance on the diagnosis, risk stratification and management of CLL, including treatment selection, sequencing of therapy, management of complications and supportive care. Recommendations were developed through a structured consensus process involving Australian and New Zealand clinicians with expertise in CLL and are endorsed by the Australasian Lymphoma Alliance, the Australasian Leukaemia and Lymphoma Group CLL Working Party and the Haematology Society of Australia and New Zealand. Levels of evidence and grades of recommendation were assigned using the Grading of Recommendations Assessment, Development and Evaluation framework.</p>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":"56 8","pages":"1421-1428"},"PeriodicalIF":1.8000,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imj.70503","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imj.70503","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

In 2023, a consensus statement on the diagnosis and management of chronic lymphocytic leukaemia (CLL) in Australasia was published. Since then, advances in clinical evidence and increased availability of molecular diagnostics and targeted therapies have further influenced contemporary CLL management. This paper provides an expert consensus update to the 2023 statement, offering current, regionally relevant guidance on the diagnosis, risk stratification and management of CLL, including treatment selection, sequencing of therapy, management of complications and supportive care. Recommendations were developed through a structured consensus process involving Australian and New Zealand clinicians with expertise in CLL and are endorsed by the Australasian Lymphoma Alliance, the Australasian Leukaemia and Lymphoma Group CLL Working Party and the Haematology Society of Australia and New Zealand. Levels of evidence and grades of recommendation were assigned using the Grading of Recommendations Assessment, Development and Evaluation framework.

查看原文本刊更多论文

澳大利亚慢性淋巴细胞白血病共识声明：2026年更新。

2023年，澳大利亚发表了一份关于慢性淋巴细胞白血病（CLL）诊断和治疗的共识声明。从那时起，临床证据的进步和分子诊断和靶向治疗的增加进一步影响了当代CLL的管理。本文提供了对2023声明的专家共识更新，提供了CLL诊断，风险分层和管理的最新区域相关指导，包括治疗选择，治疗顺序，并发症管理和支持护理。建议是通过结构化的共识过程制定的，涉及澳大利亚和新西兰具有CLL专业知识的临床医生，并得到澳大利亚淋巴瘤联盟、澳大利亚白血病和淋巴瘤小组CLL工作组以及澳大利亚和新西兰血液病学会的认可。使用建议评估、发展和评估分级框架分配证据水平和建议等级。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Internal Medicine Journal 医学-医学：内科

CiteScore

3.50

自引率

4.80%

发文量

600

审稿时长

3-6 weeks

期刊介绍： The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.